Approaches to enhance the efficacy of DNA vaccines

被引:64
作者
Manoj, S
Babiuk, LA
Littel-van den Hurk, SV
机构
[1] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
[2] Univ Saskatchewan, Dept Vet Microbiol, Saskatoon, SK S7N 0W0, Canada
关键词
DNA immunization; strategies; immune responses; plasmids; DNA vaccines; vaccine delivery; vaccine efficacy; animal models;
D O I
10.1080/10408360490269251
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
DNA vaccines consist of antigen-encoding bacterial plasmids that are capable of inducing antigen-specific immune responses upon inoculation into a host. This method of immunization is advantageous in terms of simplicity, adaptability, and cost of vaccine production. However, the entry of DNA vaccines and expression of antigen are subjected to physical and biochemical barriers imposed by the host. In small animals such as mice, the host-imposed impediments have not prevented DNA vaccines from inducing long-lasting, protective humoral, and cellular immune responses. In contrast, these barriers appear to be more difficult to overcome in large animals and humans. ne focus of this article is to summarize the limitations of DNA vaccines and to provide a comprehensive review on the different strategies developed to enhance the efficacy of DNA vaccines. Several of these strategies, such as altering codon bias of the encoded gene, changing the cellular localization of the expressed antigen, and optimizing delivery and formulation of the plasmid, have led to improvements in DNA vaccine efficacy in large animals. However, solutions for increasing the amount of plasmid that eventually enters the nucleus and is available for transcription of the transgene still need to be found. The overall conclusions from these studies suggest that, provided these critical improvements are made, DNA vaccines may find important clinical and practical applications in the field of vaccination.
引用
收藏
页码:1 / 39
页数:39
相关论文
共 236 条
[1]  
ABBAS AK, 2000, CELLULAR MOL IMMUNOL, P102
[2]  
Aints A, 1999, J GENE MED, V1, P275
[3]   Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen [J].
Al-Mariri, A ;
Tibor, A ;
Lestrate, P ;
Mertens, P ;
De Bolle, X ;
Letesson, JJ .
INFECTION AND IMMUNITY, 2002, 70 (04) :1915-1923
[4]   CODON PREFERENCES IN FREE-LIVING MICROORGANISMS [J].
ANDERSSON, SGE ;
KURLAND, CG .
MICROBIOLOGICAL REVIEWS, 1990, 54 (02) :198-210
[5]  
Armant MA, 2002, GENOME BIOL, V3
[6]   Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines [J].
Arrington, J ;
Braun, RP ;
Dong, LC ;
Fuller, DH ;
Macklin, MD ;
Umlauf, SW ;
Wagner, SJ ;
Wu, MS ;
Payne, LG ;
Haynes, JR .
JOURNAL OF VIROLOGY, 2002, 76 (09) :4536-4546
[7]   Electroporation improves the efficacy of DNA vaccines in large animals [J].
Babiuk, S ;
Baca-Estrada, ME ;
Foldvari, M ;
Storms, M ;
Rabussay, D ;
Widera, G ;
Babiuk, LA .
VACCINE, 2002, 20 (27-28) :3399-3408
[8]  
Barouch DH, 1998, J IMMUNOL, V161, P1875
[9]   PROTECTION AGAINST MYCOPLASMA-INFECTION USING EXPRESSION-LIBRARY IMMUNIZATION [J].
BARRY, MA ;
LAI, WC ;
JOHNSTON, SA .
NATURE, 1995, 377 (6550) :632-635
[10]   Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition [J].
Bauer, S ;
Kirschning, CJ ;
Häcker, H ;
Redecke, V ;
Hausmann, S ;
Akira, S ;
Wagner, H ;
Lipford, GB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) :9237-9242